Critical role of Arg59 in the high-affinity gp120-binding region of CD4 for human immunodeficiency virus type 1 infection

Virology

Volumn 363, Issue 1, 2007, Pages 69-78

  Fontenot, Danielle ^a   Jones, Jason K ^a   Hossain, Mohammad M ^b   Nehete, Pramod N ^b   Vela, Eric M ^a   Dwyer, Victor A ^a   Jagannadha Sastry, K ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Arg59; CD4 peptides; gp120 shedding; HIV 1; Infection inhibition

Indexed keywords

ARGININE; CD4 ANTIGEN; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; VIRUS ENVELOPE PROTEIN; PEPTIDE FRAGMENT;

ARTICLE; BINDING AFFINITY; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; HOST CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; VIRUS ISOLATION; VIRUS STRAIN; AMINO ACID SUBSTITUTION; CHEMISTRY; DRUG EFFECT; GENETICS; HELA CELL; HUMAN; METABOLISM; PHYSIOLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

AMINO ACID SUBSTITUTION; ANTIGENS, CD4; ARGININE; HELA CELLS; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; PEPTIDE FRAGMENTS; PROTEIN CONFORMATION;

EID: 34247634524     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2006.12.003     Document Type: Article

References (27)

1. Arthos J., Deen K., Chaikin M., Fornwald J., Sathe G., Sattentau Q., Clapham P., Weiss R., MCDougal J., and Pietropaolo C. Identification of the residues in human CD4 critical for the binding of HIV. Cell 57 (1989) 469-481
2. Berger E., Sisler J., and Earl P. Human immunodeficiency virus type 1 envelope glycoprotein molecules containing membrane fusion-impairing mutations in the V3 region efficiently undergo soluble CD4-stimulated gp120 release. J. Virol. 66 10 (1992) 6208-6212
3. Brodsky M., Warton M., Myers R., and Littman D. Analysis of the site in CD4 that binds to the HIV envelope glycoprotein. J. Immunol. 144 (1990) 3078-3086
4. Deng H., Liu R., Ellmeier W., Choe S., Unutmaz D., Burkhart M., Dimarzio P., Marmon S., Sutton R., Hill C., Davis C., Peiper S., Schall T., Littman D., and Landau N. Identification of a major co-receptor for primary isolates of HIV-1. Nature 381 (1996) 661-666
5. Drakopoulou E., Vizzavona J., and Vita C. Engineering a CD4 mimetic inhibiting the binding of the human immunodeficiency virus-1 (HIV-1) envelope glycoprotein gp120 to human lymphocyte CD4 by the transfer of a CD4 functional site to a small neutral scaffold. Lett. Pept. Sci. 5 (1998) 241-245
6. Dumonceaux J., Nisole S., Chanel C., Quivet L., Amara A., Baleux F., Briand P., and Hazan U. Spontaneous mutations in the env gene of the HIV type 1 NDK isolate are associated with CD4-independent entry phenotype. J. Virol. 72 (1998) 512-519
7. Furuta R., Wild C., Weng Y., and Weiss C. Capture of an early fusion-active conformation of HIV-1 gp41. Nat. Struct. Biol. 5 (1998) 276-279
8. Hart T., Kirsh R., Ellens H., Sweet R., Lambert D., Petteway S., Leary J., and Bugelski P. Binding of soluble CD4 proteins to human immunodeficiency virus type 1 and infected cells induces release of envelope glycoprotein gp120. Proc. Natl. Acad. Sci. 88 (1991) 2189-2193
9. Kimpton J., and Emerman M. Detection of replication competent and pseudotyped HIV with a sensitive cell line based on activation of an integrated beta-galactosidase gene. J. Virol. 66 (1992) 2232-2239
10. Kwong P., Wyatt R., Robinson J., Sweet R., Sodroski J., and Hendrickson W. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393 (1998) 648-659
11. Kwong P., Wyatt R., Majeed S., Robinson J., Sweet R., Sodroski J., and Hendrickson W. Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates. Structure 8 (2000) 1329-1339
12. Lasky L., Nakamura G., Smith D., Fennie C., Shimasaki C., Patzer E., Berman P., Gregory T., and Capon D. Delineation of a region of the human immunodeficiency virus type 1 gp120 glycoprotein critical for interaction with the CD4 receptor. Cell 50 (1987) 975-985
13. Lifson J., Hwang K., Nara P., Fraser B., Padgett M., Dunlop N., and Eiden L. Synthetic CD4 peptide derivatives that inhibit HIV infection and cytopathicity. Science 241 (1988) 712-716
14. Martin L., Stricher F., Misse D., Sironi F., Pugniere M., Barthe P., Prado-Gotor R., Freulon I., Magne X., Roumestand C., Menez A., Lusso P., Veas F., and Vita C. Rational design of a CD4 mimic that inhibits HIV-1 entry and exposes cryptic neutralization epitopes. Nat. Biotechnol. 10 (2003) 71-76
15. Morner A., Bjorndal A., Albert J., Kewalramani V., Littman D., Inoue R., Thorstensson R., Fenyo E., and Bjorling E. Primary human immunodeficiency virus type 2 (HIV-2) isolates, like HIV-1 isolates, frequently use CCR5 but show promiscuity in coreceptor usage. J. Virol. 73 (1999) 2343-2349
16. Munoz-Barroso I., Durell S., Sakaguchi K., Appella E., and Blumenthal R. Dilation of the Human Immunodeficiency Virus-1 envelope glycoprotein fusion pore revealed by the inhibitory action of a synthetic peptide from gp41. J. Cell Biol. 140 (1998) 315-323
17. Nehete P.N., Arlinghaus R.B., and Sastry K.J. Inhibition of Human Immunodeficiency Virus Type 1 infection and syncytium formation in human cells by V3 loop synthetic peptides from gp120. J. Virol. 67 (1993) 6841-6846
18. Olshevsky U., Helseth E., Furman C., Li J., Haletime W., and Sodroski J. Identification of individual human immunodeficiency virus type 1 gp120 amino acids important for CD4 receptor binding. J. Virol. 64 (1990) 5701-5707
19. Pericle F., Pinto L.A., Hicks S., Kirken R.A., Sconocchia G., Rusnak J., Dolan M.J., Shearer G.M., and Segal D.M. HIV-1 infection induces a selective reduction in STAT5 protein expression. J. Immunol. 160 (1998) 28-31
20. Peterson A., and Seed B. Genetic analysis of monoclonal antibody and HIV binding sites on the human lymphocyte antigen CD4. Cell 54 (1988) 65-72
21. Pinto L.A., Sullivan J., Berzofsky J.A., Clerici M., Kessler H.A., Landay A.L., and Shearer G.M. ENV-specific cytotoxic T lymphocytes responses in HIV seronegative health care workers occupationally exposed to HIV-contaminated body fluids. J. Clin. Invest. 96 (1995) 867-876
22. Salzwedel K., Smith E., Dey B., and Berger E. Sequential CD4-coreceptor interactions in human immunodeficiency virus type 1 Env function: soluble CD4 activates Env for coreceptor-dependent fusion and reveals blocking activities of antibodies against cryptic conserved epitopes on gp120. J. Virol. 74 (2000) 326-333
23. Sattentau Q., and Moore J. Conformation changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding. J. Exp. Med. 174 (1991) 407-415
24. Trkola A., Dragic T., Arthos J., Binley J., Olson W., Allaway G., Chen-Mayer C., Robinson J., Maddon P., and Moore J. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature 384 (1996) 184-187
25. Weiss C., and White J. Characterization of stable Chinese hamster ovary cells expressing wild-type, secreted, and glycosylphosphatidylinositol-anchored human immunodeficiency virus type 1 envelope glycoprotein. J. Virol. 67 (1993) 7060-7066
26. Wu L., Gerard N., Wyatt R., Choe H., Parolin C., Ruffing N., Borsetti A., Cardoso A., Desjardin E., Newman W., Gerard C., and Sodroski J. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature 384 (1996) 179-183
27. Wyatt R., and Sodroski J. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 280 (1998) 1884-1888